Co‐administration of proton pump inhibitors delays elimination of plasma methotrexate in high‐dose methotrexate therapy

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Co‐administration of proton pump inhibitors (PPIs) increases plasma methotrexate (MTX) concentration in cancer patients receiving high‐dose MTX (HDMTX) therapy. • There is controversy as to whether or not co‐administration of PPIs affects plasma MTX elimina...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of clinical pharmacology 2009-01, Vol.67 (1), p.44-49
Hauptverfasser:	Suzuki, Kunihiro, Doki, Kosuke, Homma, Masato, Tamaki, Hirofumi, Hori, Satoko, Ohtani, Hisakazu, Sawada, Yasufumi, Kohda, Yukinao
Format:	Artikel
Sprache:	eng
Schlagworte:	ABCG2 Adolescent Adult Aged Antimetabolites, Antineoplastic - administration & dosage Antimetabolites, Antineoplastic - metabolism ATP Binding Cassette Transporter, Sub-Family G, Member 2 ATP-Binding Cassette Transporters - metabolism Biological and medical sciences Biological Transport - drug effects breast cancer resistance protein delayed elimination Drug Interactions Female Humans Logistic Models Male Medical sciences methotrexate Methotrexate - administration & dosage Methotrexate - metabolism Middle Aged multiple logistic regression analysis Neoplasm Proteins - metabolism Neoplasms - drug therapy Neoplasms - metabolism Pharmacology. Drug treatments proton pump inhibitors Proton Pump Inhibitors - pharmacokinetics Proton Pump Inhibitors - pharmacology Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!